Mesenchymal Stromal Cells (MSC), as advanced therapy products, must satisfy all the requirements for human use of medicinal products, aiming to maintain the quality and safety of the cells. The MSC manufacturing process for clinical use should comply with the principles of Good Manufacturing Practice (GMP). This ensures that cell preparations are produced and controlled, from the collection and manipulation of raw materials, through the processing of intermediate products, to the quality controls, storage, labelling and packaging, and release.
For reasons of clarity, complex therapeutic products such as the Advanced Therapy Medicinal Products (ATMPs) require a precise legal definition. The Regulation defines ATMPs as the gene therapy medicinal products, the somatic cell therapy medicinal products and the tissue-engineered products. Each of these products has specific pharmacologic, metabolic and immunologic activities and the potential for treating a variety of disorders. For these reasons, cellular products for ATMPs, prepared on a routine basis, must meet the same stringent conditions required for drugs before they are placed on the market. In particular, their activity, efficacy, safety and required dose must be defined. Furthermore, they must be manipulated according to the Good Manufacturing Practice (GMP) [2] , and they require preclinical testing in Good Laboratory Practice (GLP) and clinical trials conducted in Good Clinical Practice (GCP) before being commercialized [3] .
In the last decade one cell type in particular, the mesenchymal stromal cells (MSCs), have attracted great interest due to the numerous applications proposed for their use [4] . Thanks to their intrinsic properties, MSCs represent an attractive candidate for clinical applications [5] [6] [7] .
However, as ATMPs, they must satisfy all the above-mentioned requirements.
Therefore, the quality and safety of the expanded MSCs must be maintained throughout their production and quality control cycle, ensuring their safe use in the Mesoblast's) Prochymal. Smaller academic-investigator-driven trials have also been conducted in medical centres and academic institutions in Europe, showing the safety of allogeneic MSC therapy [10] [11] .
The Guideline on human cell-based medicinal products, issue by EMA on 2008, is a useful document for stem cell production for marketing authorization application, covering the manufacturing process, quality considerations, process validation and clinical considerations [12] . Manufacturing and quality control issues are frequently under discussion during the regulatory authorization processes. The recent paper of Wuchter summarizes a consensus meeting between researchers, clinicians and regulatory experts on standard quality requirements for MSC production [13] .
However, a practical guideline for standardization of isolation, expansion and characterization methods is missing. Moreover, quality controls of starting material, intermediate and final products should also be considered, as MSCs must be produced in compliance with GMP to ensure reproducibility, efficacy and safety of the clinical product.
Even if the Regulations for biological active substances as GMP Annex 2 [14] can help the ATMP's manufacturer to comply with the GMP requirements, the common opinion is that these regulations are still not enough to cover all the Authority requirements for safety, efficacy and potency related to the ATMP's.
However, a specific step-by-step guideline for MSCs is not available to date. The aim of this document is to clarify the critical control points that must be considered during the process of expansion and release of MSC as ATMPs. For this purpose, the document will evaluate the most important steps of GMP production for the application of clinical trials with MSCs. These steps include: 1) the isolation, identification and expansion process; 2) the validation phase of the process, including all quality controls for MSC characterization, functionality, potency and safety; 3) the quality control at the batch release to guarantee the safety of patient infusion. This last step is also applied to products that must be cryopreserved, assuming that the cryopreservation process has been validated during the validation phase. The thawing phase is not covered by this document.
Isolation and expansion of mesenchymal stromal cells (MSCs)
The term "mesenchymal stem cells" initially referred to multilineage progenitor cells isolated and culture-expanded from human adult bone marrow (BM), that once in culture display a heterogeneous morphology and are capable of several subpopulations. Horwitz and the International Society for Cellular Therapy (ISCT) [15] better defined them as "mesenchymal stromal cells".
Although BM is still the most common source of MSCs, during the last two decades alternative and more accessible tissue sources of MSCs have been identified. For instance, MSCs have been isolated from tissues, such as fat, deciduous teeth, placenta and umbilical cord blood, showing comparable features to BM-derived cells [16] [17] . In particular, fresh umbilical cord blood (UCB) is the third common source for For the purpose of this paper, the intended source of MSCs, for which there are scientifically proven clinical applications, are bone marrow, umbilical cord blood, adipose tissue, placenta (www.clinicaltrials.gov).
All the reagents and materials used during the manufacturing of the cell-based This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
considering the medium, the use of animal-derived supplements, the plastic, and the density and number of passages, should be carried out on at least three representative MSC samples.
Quality control for validation of MSC production
The quality and safety of MSCs must be maintained throughout their production and quality control cycle, ensuring their final use in the patient. According to International Conference on Harmonization Q2 (ICH Q2
The process should follow a validation protocol, also considering instruments, supplies and reagents, and defining roles and responsibilities of each step [39] . A useful scheme of manufacturing and quality control processes of MSC production as a cell therapy medicinal product is represented by Galvez [40] . In figure 1 two flowcharts on validation and production processes are represented. A validation protocol on a minimum of three expansion procedures should be implemented to standardize the best culture condition and to demonstrate the safety and feasibility of the production protocol.
Results from method validation can be used to judge the quality, reliability and consistency of analytical results [39] .
The elements of the analytical method requiring proof through validation as contained in the ICH Q2A guidelines are specificity, accuracy, precision, repeatability, linearity and range, as shown in table 2. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
complete commercial chondrogenic medium as cellular aggregates floating freely in suspension culture; after inclusion in paraffin, the pellet could be stained with Alcian Blue to identify the presence of hyaluronic acid and sialomucin.
The multipotent capacity should be demonstrated for all three of the differentiative lineages.
MSCs are a promising tool for cell therapies also for their immunomodulant proprieties, thanks to their paracrine production of trophic factors together with their broad immune modulatory and anti-inflammatory functions [43] .
The recent paper of Menard and Krampera [44] suggested some reproducible immunological assays to quantify the immune-modulatory properties of MSCs produced according to GMP. However, these analysis are recommended in the validation (or in pre-clinical) phase, but not mandatory for the release of MSC.
Growth characteristics
The cellular expansion growth rate of MSCs should be evaluated by counting the cell at each passage and expressed in terms of CPD using the formula log N/ log 2, where N is the cell number of the confluent monolayer divided by the initial number of cells seeded [45] .
For clinical safety issues, the expansion should not exceed 4 passages, in an attempt to minimize the administration of senescent cells.
Sterility
For microbiological control, the sterility should be evaluated at each passage on a representative sample of the products, containing cells (EuPh 2.6.27). Due to the This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
small volume of the cell-based medicinal products, the analysis is commonly performed on the supernatant. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Karyotype
In order to demonstrate that the expansion method maintain the genomic stability during the in vitro culture period, the karyotype analysis should be performed. Some studies reported that human MSCs retained chromosomal stability following long-term culture in vitro [47] [48] . Tarte showed that MSCs with or without chromosomal alterations, became senescent, without evidence of transformation either in vitro or in vivo, assuming that karyotyping and FISH results are not informative and are thus not adequate controls for the release of MSCs for clinical uses [49] . The analysis of Ben-David at colleagues [50] , reveals that MSCs have a 4% probability of acquiring chromosomal abnormalities. However, this study has been argued by Sensebè's group [51] .
Recently, Capelli's group performed a large study, by conventional karyotype analysis, on 92 clinical grade BM-derived MSCs, showed the presence of only spontaneous non-clonal anomalies, assuming that the lack of clonal aberrations or the presence of non-clonal anomalies on 10% of the analysed metaphases should be set as the release criteria for MSCs distribution [52] . This is on line with the Cell Products Working Party, in which, it has been proposed, that a karyotype or FISH analysis should be necessary, at batch release, only in cases in which recurrent chromosomal anomalies are found [53] .
The demonstration of the absence of genetic instability by karyotype analysis should be assessed by molecular [54] or conventional methods (G banding). At least 20 metaphases should be analysed, and in the presence of aberrations, 20 more metaphases are requested, as defined by the General Guidelines and Quality Assurance for Cytogenetics [47, [55] [56] . The karyotyping analysis would be sufficient as a release test with the exclusion of two identical abnormal metaphases on 20 This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
metaphases analysed (10%) [53] , comparing the final batch to the donor/patient karyotype status.
Quality control in-process for MSCs
For identity, morphology, immunophenotype and growth characteristics MSCs can be evaluated as described for the validation phase.
For microbiological in-process control, the sterility should be evaluated on cells and on supernatant samples, by rapid microbiology methods (EuPh 2.6.27) or by classical methods (EuPh 2.6.1) by a GMP approved Quality Control laboratory [40] .
The quality control analysis and GMP batch release testing, is part of the manufacturing process. For this reason, these tests should be carried out in the same GMP facility, in a dedicated and validated laboratory or as outsource in laboratories providing this service in compliance with GMPs.
Quality control at batch release for MSCs
At batch release, MSCs should be analysed for morphology and immunophenotype, as previously described. In addition, the following tests should be carried out. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Identity
should be assessed only in case it is necessary to share spaces and instruments for the processing of different donors.
Sterility
Bacteriology, LAL test and mycoplasma should be analyzed as previously described.
For microbiological control, the sterility should be evaluated on cells and on supernatant samples, according to current European Pharmacopoeia by an accredited laboratory.
The rapid microbiology methods applied to ATMP's are commonly methods to substitute time consuming testing as Sterility testing and Mycoplasma testing. These rapid tests are described in the European Pharmacopoeia and the methods for validation are also described in details. In particular, the chapter EuPh 2. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Similarly, reagents of swine origin-like proteolytic enzymes have to tested by NAT techniques or by inoculation in susceptible cell cultures to detect virus contamination.
Mycoplasma detection has to be carried out by the methods previously reported.
A summary panel of required quality controls is shown in table 3.
Batch control sample
A sizable aliquot of the final batch should be cryopreserved as a backup in order to further analyze the cells in case of a clinical need.
Conclusion
MSC production according to GMP requirements is an important issue that has emerged in recent years. Currently there is no consensus on quality standards for the production of MSC for clinical application. In this paper the GISM Working Group has identified the minimal quality criteria for MSCs at different production stages.
As the recent work of a group of German researchers pointed out the manufacturing and quality control issues [13] , we hope that our work could be a significant first step forward the awareness of the Regulatory Authority that a wider agreement on this matter is the needing. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
